Durability of Immunity Is Low Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1, BA.2, and BA.3 Variants After Second and Third Vaccinations in Children and Young Adults With Inflammatory Bowel Disease Receiving Biologics.
Durability of Immunity Is Low Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1, BA.2, and BA.3 Variants After Second and Third Vaccinations in Children and Young Adults With Inflammatory Bowel Disease Receiving Biologics.
复制标题
DOI：
10.1053/j.gastro.2022.08.009
复制
发表时间：
2022-12
期刊：
影响因子：
29.4
通讯作者：
中科院分区：
文献类型：
--
作者：
“”
The continued emergence of Omicron variants during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged infection control and posed a risk to individuals with inflammatory bowel disease (IBD) despite vaccination. Previous data suggest an attenuated response to vaccination in adult patients with IBD receiving anti–tumor necrosis factor and other immunomodulatory therapy. 1, 2 We previously observed a blunted antibody response in children and young adults receiving biologics after SARS-CoV-2 infection. 3The Omicron variant (B. 1.529. 1/BA. 1) became the dominant variant of concern as it spreads around the globe in November 2021. 4 Since then, subvariants of Omicron emerged (BA. 2 and BA. 3), each with its own set of mutations from SARS-CoV-2 infection or vaccination-induced antibodies (Supplementary Table 1). 5, 6 Thus far, the BA. 2 variant demonstrates higher transmissibility compared with BA. 1 and has reached dominance in several countries. 4 Individuals with IBD who are receiving biologic therapies have a blunted antibody response to SARS-CoV-2 infection. 3 However, limited knowledge exists regarding neutralizing antibodies after 2 doses vs 3 doses of mRNA vaccination and their durability against SARS-CoV-2 Omicron lineages in children and young adults with IBD receiving therapeutics.
登录
查看更多内容
DOI：
10.1016/j.cgh.2022.02.030
发表时间：
2022-07
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
Jena A;James D;Singh AK;Dutta U;Sebastian S;Sharma V
通讯作者：
Sharma V
影响因子：
4.7
作者：
Vollenberg R;Tepasse PR;Kühn JE;Hennies M;Strauss M;Rennebaum F;Schomacher T;Boeckel G;Lorentzen E;Bokemeyer A;Nowacki TM
通讯作者：
Nowacki TM
影响因子：
5.8
作者：
Tang J;Lee Y;Ravichandran S;Grubbs G;Huang C;Stauft CB;Wang T;Golding B;Golding H;Khurana S
通讯作者：
Khurana S
影响因子：
82.9
作者：
Khoury, David S.;Cromer, Deborah;Davenport, Miles P.
通讯作者：
Davenport, Miles P.
影响因子：
4.9
作者：
Dailey J;Kozhaya L;Dogan M;Hopkins D;Lapin B;Herbst K;Brimacombe M;Grandonico K;Karabacak F;Schreiber J;Liang BT;Salazar JC;Unutmaz D;Hyams JS
通讯作者：
Hyams JS